Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The said inspection was concluded with no form 483 observation.
Alkem Laboratories Ltd dropped for a fifth straight session today. The stock is quoting at Rs 4993.5, down 0.21% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.65% on the day, quoting at 22740.8. The Sensex is at 73490.15, down 0.49%.Alkem Laboratories Ltd has eased around 6.34% in last one month.Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has eased around 5.7% in last one month and is currently quoting at 25615, down 0.93% on the day. The volume in the stock stood at 25391 shares today, compared to the daily average of 1.39 lakh shares in last one month.
The benchmark October futures contract for the stock is quoting at Rs 4991, down 0.26% on the day. Alkem Laboratories Ltd tumbled 9.77% in last one year as compared to a 12.17% slide in NIFTY and a 12.88% spurt in the Nifty Pharma index.
The PE of the stock is 26.65 based on TTM earnings ending June 26.
Alkem Laboratories Ltd, SBI Cards & Payment Services Ltd, ERIS Lifesciences Ltd, Medplus Health Services Ltd are among the other stocks to see a surge in volumes on BSE today, 07 October 2026.
TBO Tek Ltd witnessed volume of 1.28 lakh shares by 10:45 IST on BSE, a 25.38 times surge over two-week average daily volume of 5061 shares. The stock increased 2.50% to Rs.1,735.00. Volumes stood at 3214 shares in the last session.
Alkem Laboratories Ltd registered volume of 53227 shares by 10:45 IST on BSE, a 8.42 fold spurt over two-week average daily volume of 6324 shares. The stock rose 1.69% to Rs.5,351.70. Volumes stood at 5660 shares in the last session.
SBI Cards & Payment Services Ltd clocked volume of 3.89 lakh shares by 10:45 IST on BSE, a 7.76 times surge over two-week average daily volume of 50075 shares. The stock lost 1.70% to Rs.562.20. Volumes stood at 56565 shares in the last session.
ERIS Lifesciences Ltd witnessed volume of 31834 shares by 10:45 IST on BSE, a 7.49 times surge over two-week average daily volume of 4251 shares. The stock dropped 0.45% to Rs.1,182.30. Volumes stood at 2663 shares in the last session.
Medplus Health Services Ltd recorded volume of 29239 shares by 10:45 IST on BSE, a 5.59 times surge over two-week average daily volume of 5229 shares. The stock lost 0.62% to Rs.646.00. Volumes stood at 5157 shares in the last session.
He will cease to hold the position of senior management personnel with effect from 30 September 2026.
In his resignation letter, Agrawal said he had decided to step down to pursue professional opportunities that align more closely with his long-term professional and personal growth.
Agrawal said he would continue to support the management to ensure a seamless handover of ongoing strategic initiatives and would serve through 30 September 2026.
During his tenure, Agrawal said he supported the group's strategic initiatives, including building the MedTech business, the acquisition of Adroit, creation of Alkem Wellness, formation of a Saudi joint venture and acquisition of Bombay Ortho.
He also mentioned the liquidation of idle assets, including the Indore SEZ plant, improving returns on treasury income and implementing new UCPMP marketing guidelines in the domestic market. More recently, he led the acquisition of Occlutech.
The company did not provide details of Agrawal's successor in the exchange filing.
Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.
The company had reported 21.72% fall in consolidated net profit to Rs 519.95 crore despite a 10.95% rise in revenue to Rs 3,740.15 crore in Q1 FY27 over Q1 FY26.
Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5297, up 2.36% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.51% on the day, quoting at 23336.3. The Sensex is at 74579.47, up 0.33%. Alkem Laboratories Ltd has dropped around 3.25% in last one month.
Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 0.57% in last one month and is currently quoting at 26146.2, up 1.4% on the day. The volume in the stock stood at 78414 shares today, compared to the daily average of 1.33 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 5310, up 1.68% on the day. Alkem Laboratories Ltd is down 3.33% in last one year as compared to a 8.21% drop in NIFTY and a 17.44% drop in the Nifty Pharma index.
The PE of the stock is 27.68 based on TTM earnings ending June 26.
The Fed’s indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction.
Pharma shares jumped after declining in the past five consecutive trading sessions.
At 13:27 IST, the barometer index, the S&P BSE Sensex jumped 51.75 points or 0.06% to 74,383.03. The Nifty 50 index added 53.65 points or 0.24% to 23,269.85.
The broader market outperformed frontline indices. The BSE 150 MidCap Index jumped 0.90% and the BSE 250 SmallCap Index rose 0.71%.
The market breadth was strong. On the BSE, 2,517 shares rose and 1,707 shares fell. A total of 235 shares were unchanged.
Trump Tariffs:
The US House of Representatives on Wednesday passed a Russia sanctions bill by 262-159 that gives President Donald Trump the power to impose tariffs of up to 100% on countries buying Russian oil and gas, directly targeting major importers such as India and China. The bill, which follows Senate approval on 7 August 2026, also expands sanctions on Russian officials, financial institutions and vessels linked to Russia's shadow fleet, while extending existing Iran sanctions by five years.
IPO Update:
National Stock Exchange of India (NSE) received bids for 2,98,19,560 shares as against 8,86,42,911 shares on offer, according to stock exchange data at 14:27 IST on 16 September 2026. The issue was subscribed 0.34 times.
The issue opened for bidding on 17 September 2026 and will close on 19 September 2026. The price band of the IPO is fixed between Rs 1,700 and 1,785 per share. An investor can bid for a minimum of 8 equity shares and multiples thereof.
Hero Motors received bids for 25,08,64,122 shares as against 8,86,07,596 shares on offer, according to stock exchange data at 14:27IST on 17 September 2026. The issue was subscribed 2.83 times.
The issue opened for bidding on 16 September 2026 and will close on 18 September 2026. The price band of the IPO is fixed between Rs 79 and 84 per share. An investor can bid for a minimum of 178 equity shares and multiples thereof.
Buzzing Index:
The Nifty Pharma index jumped 1.28% to Rs 26,480.80. The index declined 2.73% in the past five consecutive trading sessions
Alkem Laboratories (up 3.36%), Gland Pharma (up 3%), Aurobindo Pharma (up 2.88%), Dr Reddys Laboratories (up 2.81%), Laurus Labs (up 2.45%), Lupin (up 2.14%), Zydus Lifesciences (up 2%), Mankind Pharma (up 1.76%), Divis Laboratories (up 1.62%) and Biocon (up 1.54%) surged.
Numbers to Track:
The yield on India's 10-year benchmark federal paper fell 0.11% to 7.047 compared with the previous session close of 7.055.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 95.9200 compared with its close of 95.9100 during the previous trading session.
MCX Gold futures for 5 October 2026 settlement fell 0.64% to Rs 1,51,493.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.04% to 100.21.
The United States 10-year bond yield fell 0.32% to 4.988.
In the commodities market, Brent crude for the November 2026 settlement declined $1.40 or 1.32% to $104.43 a barrel.
Stock in Spotlight:
Semiconductor and electronics manufacturing stocks were in demand on Thursday, 17 September 2026, as SEMICON India 2026 got underway at Yashobhoomi in New Delhi. The three-day event is being held from 17 to 19 September under the theme 'Silicon to Systems: Building the Ecosystem'
Syrma SGS Technology was the top gainer, rising 7.11%. MosChip Technologies surged 4.95%, followed by Kaynes Technology India, which gained 4.71%. Dixon Technologies advanced 1.11%, while Avalon Technologies rose 1.07%.
Prime Minister Narendra Modi inaugurated SEMICON India 2026 on Thursday. The event brings together companies, policymakers, investors, researchers, startups and academic institutions from across the semiconductor and electronics value chain. The PMO said more than 600 companies and representatives from 52 countries are participating.
Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy and is available in various strengths.
Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition.
Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life.
NeuCeno (cenobamate) acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing, while enhancing the brain's natural inhibitory signaling via positive modulation of GABA-A receptors.
In randomized clinical studies of adults with uncontrolled focal seizures on existing anti-seizure medications, adjunctive cenobamate produced up to 78% reduction in seizure frequency, with up to 30% patients achieving seizure freedom during the maintenance phase.
Sandeep Singh, managing director, Alkem Laboratories, said: 'People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management.
At Alkem, we believe patients deserve access to advanced treatment options that can help address unmet medical needs.
With the launch of NeuCeno (cenobamate), we reaffirm our commitment to improving patient care by enabling access to an important therapeutic option and supporting healthcare professionals in making informed treatment decisions for adults living with partial-onset seizures.'
The company had reported 21.72% fall in consolidated net profit to Rs 519.95 crore despite a 10.95% rise in revenue to Rs 3,740.15 crore in Q1 FY27 as compared with Q1 FY26.
The scrip rose 0.57% to currently trade at Rs 5184.20 on the BSE.
Dr Lal Pathlabs Ltd, Alkem Laboratories Ltd, Apollo Tyres Ltd, Torrent Pharmaceuticals Ltd are among the other stocks to see a surge in volumes on BSE today, 16 September 2026.
Tata Chemicals Ltd clocked volume of 5.15 lakh shares by 10:45 IST on BSE, a 13.42 times surge over two-week average daily volume of 38377 shares. The stock gained 0.23% to Rs.736.20. Volumes stood at 43739 shares in the last session.
Dr Lal Pathlabs Ltd registered volume of 58209 shares by 10:45 IST on BSE, a 9.56 fold spurt over two-week average daily volume of 6086 shares. The stock slipped 0.26% to Rs.1,900.00. Volumes stood at 10622 shares in the last session.
Alkem Laboratories Ltd clocked volume of 51711 shares by 10:45 IST on BSE, a 5.42 times surge over two-week average daily volume of 9545 shares. The stock gained 1.45% to Rs.5,230.00. Volumes stood at 9762 shares in the last session.
Apollo Tyres Ltd clocked volume of 1.24 lakh shares by 10:45 IST on BSE, a 4.88 times surge over two-week average daily volume of 25367 shares. The stock gained 0.78% to Rs.409.35. Volumes stood at 16215 shares in the last session.
Torrent Pharmaceuticals Ltd saw volume of 43939 shares by 10:45 IST on BSE, a 4.5 fold spurt over two-week average daily volume of 9774 shares. The stock dropped 1.05% to Rs.4,799.15. Volumes stood at 6237 shares in the last session.
Alkem Laboratories announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients.
Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets.
Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition. Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life.
NeuCeno (cenobamate) acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing, while enhancing the brain's natural inhibitory signaling via positive modulation of GABA-A receptors. In randomized clinical studies of adults with uncontrolled focal seizures on existing anti-seizure medications, adjunctive cenobamate produced up to 78% reduction in seizure frequency, with up to 30% patients achieving seizure freedom during the maintenance phase.